
INTERNATIONAL JOURNAL OF JUDICIAL SCIENCE RESEARCH STUDIES (IJJSRS)

(Open Access, Double-Blind Peer Reviewed Journal)

ISSN Online: 3049-0618 ISSN Print: 3108-2785



Digital Minds, Analog Laws: A Comparative Study of Regulatory Frameworks Governing Mental Health Telemedicine in India, the US, and the UK

Varsha P[1], Ch. Venkateswarlu[2]

[1] Research Scholar, School of Law, Vels Institute of Science, Technology & Advanced Studies, Pallavaram, Chennai, India.
[2] Associate Professor, School of Law, Vels Institute of Science, Technology & Advanced Studies, Chennai, India.

Article information

Received: 14th August 2025
Received in revised form: 20th September 2025
Accepted: 18th October 2025
Available online: 21st November 2025

Volume: 2
Issue: 4
DOI: https://doi.org/10.63090/IJJSRS/3049.0618.0038

Abstract

India faces a mental health crisis of staggering proportions, with an estimated 83% treatment gap and fewer than 0.3 psychiatrists per 100,000 population. Telemedicine has emerged as a transformative mechanism for bridging this gap, as evidenced by the Tele-MANAS programme's reach to over two million callers, 35% of whom were first-time mental health seekers. However, India's regulatory framework creates significant legal barriers to tele-psychiatry and digital mental health service delivery. This article undertakes a comparative legal analysis of mental health telemedicine regulation across three jurisdictions: India, the United States, and the United Kingdom. The analysis examines five regulatory dimensions: prescribing restrictions for controlled substances, informed consent standards, licensure and cross-jurisdictional practice, quality assurance and accreditation, and data protection for mental health records. The article argues that the Telemedicine Practice Guidelines 2020's blanket List B prohibition on psychotropic medications, the Mental Healthcare Act 2017's silence on telemedicine-based service delivery, and the absence of tele-psychiatry-specific informed consent standards collectively constitute a regulatory architecture that is fundamentally misaligned with the constitutional right to mental healthcare. Drawing on the US and UK models, the article proposes specific legislative and regulatory reforms, including amendments to the TPG 2020's prescribing restrictions, explicit integration of telemedicine within the Mental Healthcare Act framework, and the development of national tele-psychiatry practice standards.

Keywords: - Tele-Psychiatry, Mental Health Telemedicine, Mental Healthcare Act 2017, Ryan Haight Act, Psychotropic Prescribing, Treatment Gap, India, Comparative Law

I. INTRODUCTION

Mental illness constitutes the leading cause of disability worldwide, yet the global mental health treatment gap the proportion of individuals with mental disorders who receive no treatment remains alarmingly wide. In low- and middle-income countries, this gap exceeds 75%, and in India, it reaches an estimated 83%, meaning that more than four out of every five Indians with a diagnosable mental health condition receive no treatment whatsoever (World Health Organization [WHO], 2022). The magnitude of this gap is compounded by India's severe shortage of mental health professionals: the country has approximately 0.3 psychiatrists, 0.07 psychologists, and 0.07 social workers per 100,000 population, against WHO-recommended ratios that are orders of magnitude higher (National Institute of Mental Health and Neurosciences [NIMHANS], 2016).

Telemedicine, and specifically tele-psychiatry, has been widely recognised as a high-potential mechanism for addressing this gap. The inherent characteristics of mental health consultations primarily verbal interaction, limited reliance on physical examination, amenability to structured therapeutic protocols, and high patient sensitivity to stigma make psychiatry one of the medical specialties most naturally suited to remote delivery (Hilty et al., 2013). Evidence from high-income

countries demonstrates that tele-psychiatry achieves clinical outcomes comparable to in-person care across multiple conditions, including depression, anxiety disorders, post-traumatic stress disorder, and substance use disorders (Hubley et al., 2016). India's own Tele-MANAS programme, launched in 2022, has provided preliminary evidence of telemedicine's capacity to reach underserved populations: by 2024, the programme had received over two million calls, with 35% of callers seeking mental health support for the first time (Ministry of Health and Family Welfare [MoHFW], 2024).

Despite this potential, India's regulatory framework creates significant legal barriers to the delivery of mental health services through telemedicine. The Telemedicine Practice Guidelines 2020 (TPG) impose blanket restrictions on the teleconsultation prescribing of psychotropic medications classified under List B, including commonly prescribed antidepressants, anxiolytics, and antipsychotics (Board of Governors in supersession of Medical Council of India, 2020). The Mental Healthcare Act 2017 (MHCA), India's landmark mental health legislation, makes no reference to telemedicine as a modality for service delivery, creating uncertainty about the Act's application to tele-psychiatric consultations (Parliament of India, 2017). There are no tele-psychiatry-specific informed consent standards, quality assurance frameworks, or data protection requirements for mental health records. These regulatory gaps exist not in isolation but against a constitutional backdrop in which the Supreme Court has repeatedly affirmed the right to healthcare, including mental healthcare, as a facet of the right to life under Article 21 of the Constitution (Paschim Banga Khet Mazdoor Samity v. State of West Bengal, 1996), and the right to informational privacy, including health data privacy, recognised in K.S. Puttaswamy v. Union of India (2017).

This article undertakes a comparative legal analysis of mental health telemedicine regulation in India, the United States, and the United Kingdom. These jurisdictions are selected for their contrasting regulatory approaches: the US represents a federalised system with specific controlled substance telemedicine legislation (the Ryan Haight Act) and extensive state-level tele-psychiatry regulation; the UK represents a centralised system with integrated quality assurance through the Care Quality Commission (CQC) and detailed clinical guidance for remote mental health consultations. The comparison illuminates the specific regulatory mechanisms that India lacks and the reform pathways available within its constitutional and institutional framework.

II. THE MENTAL HEALTH TREATMENT GAP: DIMENSIONS OF THE CRISIS

The scale of India's mental health crisis provides the normative foundation for regulatory reform. The National Mental Health Survey 2015-16, conducted by NIMHANS across twelve states, estimated that 10.6% of India's adult population approximately 150 million people suffered from a mental health disorder, with common mental disorders (depression, anxiety) affecting 5.2% and severe mental disorders (schizophrenia, bipolar disorder) affecting 1.9% (NIMHANS, 2016). Subsequent studies have revised these estimates upward, particularly following the COVID-19 pandemic. The Lancet Psychiatry Commission on mental health in India estimated the economic cost of mental illness at $1.03 trillion between 2012 and 2030, through lost productivity, healthcare expenditure, and premature mortality (Patel et al., 2016).

The treatment gap is driven by intersecting barriers. Geographic barriers are paramount: 68% of India's population resides in rural areas where mental health services are virtually non-existent. The district mental health programme, despite being operational since 1996, covers fewer than 300 of India's 766 districts with functional mental health services (Murthy, 2017). Economic barriers compound geographic ones: out-of-pocket expenditure constitutes approximately 62% of India's total health expenditure, and mental healthcare which often requires sustained treatment over months or years is particularly susceptible to catastrophic health spending (National Health Accounts, 2020). Stigma remains the most pervasive barrier: studies consistently demonstrate that stigma deters treatment-seeking across all socioeconomic strata, with patients fearing social ostracism, employment discrimination, and marital consequences (Shidhaye & Kermode, 2013).

The COVID-19 pandemic dramatically amplified India's pre-existing mental health crisis. A systematic review and meta-analysis published in the Indian Journal of Psychiatry estimated that the prevalence of depression among Indians during the pandemic rose to 28.7%, anxiety to 25.1%, and stress-related disorders to 22.4%, representing a significant escalation over pre-pandemic baselines (Lakhan et al., 2022). The pandemic's collateral effects prolonged lockdowns, economic disruption, social isolation, fear of infection, and grief from mass bereavement created what the WHO described as a 'massive increase in demand for mental health services' at a time when in-person services were simultaneously disrupted (WHO, 2022). Substance use disorders, particularly alcohol dependence, surged following the abrupt imposition and subsequent lifting of prohibition-style lockdown measures, overwhelming the limited de-addiction infrastructure (Murthy, 2020). India's suicide rate, already among the highest globally, reached 12.4 per 100,000 in 2021, with over 164,000 recorded suicides a figure widely acknowledged to be an undercount (National Crime Records Bureau [NCRB], 2022). The decriminalisation of attempted suicide under Section 115 of the Mental Healthcare Act 2017 which provides that notwithstanding anything contained in Section 309 of the Indian Penal Code, any person who attempts to commit suicide shall be presumed to be under severe stress and shall not be tried or punished was a progressive legislative step, yet its practical impact remains limited when the individuals it seeks to protect cannot access the mental health services the Act promises. The pandemic period also demonstrated the potential of tele-psychiatry: the Tele-MANAS helpline, launched in October 2022 specifically in response to the pandemic's mental health aftermath, recorded over 780,000 calls in its first six months, confirming that demand for remote mental health support was both massive and previously unmet (MoHFW, 2024). The lesson of the pandemic is unambiguous: India requires a mental health service delivery model that can function at scale, withstand disruptions to physical infrastructure, and reach populations that the traditional clinic-based model has structurally failed to serve.

Telemedicine addresses each of these barriers with specific mechanisms. Geographic barriers are overcome through remote consultation, enabling patients in rural areas to access psychiatrists and psychologists located in urban centres. Economic barriers are partially mitigated through reduced travel costs, time savings, and the lower overhead costs of digital delivery. Most significantly, telemedicine addresses stigma through the privacy of remote consultation: a patient accessing psychiatric care from their home is not visible in a hospital waiting room, and digital platforms can offer anonymised initial consultations. The Tele-MANAS data confirms this mechanism: the programme reported that 35% of its callers were first-

time mental health seekers who had not previously accessed any mental health service, suggesting that the telemedicine modality itself lowered the threshold for help-seeking (MoHFW, 2024). The question, therefore, is not whether telemedicine can address the mental health treatment gap, but whether India's legal framework permits it to do so.

III. INDIA'S REGULATORY FRAMEWORK: THE TPG 2020 AND THE MENTAL HEALTH CARE ACT 2017

3.1. The Telemedicine Practice Guidelines 2020 and Psychotropic Prescribing

The Telemedicine Practice Guidelines 2020, issued by the Board of Governors in supersession of the Medical Council of India under the authority of the Indian Medical Council Act 1956, classify medications into three lists for the purposes of teleconsultation prescribing. List A encompasses over-the-counter medications and common prescription drugs that may be prescribed via any telemedicine modality (video, audio, or text). List B encompasses medications that may only be prescribed via video consultation, and only for re-prescribing where the patient has a prior in-person prescription. List B explicitly includes "anti-anxiety, anti-depressants, anti-psychotics" and other psychotropic medications. List C encompasses medications that cannot be prescribed through telemedicine under any circumstances, including narcotics and controlled substances under the NDPS Act 1985 (Board of Governors, 2020).

The List B restriction creates a critical bottleneck for tele-psychiatric care. Under the TPG framework, a psychiatrist conducting a first-time teleconsultation with a patient presenting with major depressive disorder cannot prescribe a selective serotonin reuptake inhibitor (SSRI) the first-line treatment for depression unless the patient has a prior in-person prescription from another physician. This requirement effectively mandates at least one in-person consultation before tele-psychiatric treatment can commence, negating the very purpose of tele-psychiatry for the populations it is most needed to serve: rural patients without geographic access to a psychiatrist, patients deterred by stigma from visiting a mental health facility, and patients in crisis requiring immediate pharmacological intervention.

The pharmacological basis for the blanket List B prohibition is particularly difficult to justify when the safety profiles of individual psychotropic medications are examined. Selective serotonin reuptake inhibitors (SSRIs) including fluoxetine, sertraline, escitalopram, and paroxetine are the first-line pharmacological treatment for major depressive disorder, generalised anxiety disorder, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder. SSRIs have a wide therapeutic window, meaning that the margin between the effective dose and the toxic dose is large, substantially reducing the risk of accidental or intentional overdose. Unlike older tricyclic antidepressants, SSRIs are not lethal in overdose in the vast majority of cases, a critical safety consideration for psychiatric patients who may be at risk of self-harm (Cipriani et al., 2018). SSRIs have no abuse potential, do not produce euphoria or dependence, and are not diverted for recreational use. Serotonin-norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine and duloxetine share a similar safety profile: wide therapeutic window, minimal abuse potential, and well-characterised side-effect profiles that can be adequately discussed and monitored remotely. Non-benzodiazepine anxiolytics such as buspirone similarly present minimal abuse or diversion risk. By contrast, benzodiazepines including diazepam, alprazolam, clonazepam, and lorazepam do carry genuine clinical concerns for remote prescribing: they produce physiological dependence with regular use, have significant abuse and diversion potential, interact dangerously with alcohol and opioids, and their abrupt discontinuation can cause life-threatening withdrawal seizures (Lader, 2011). A risk-proportionate regulatory framework would differentiate between these categories: permitting remote initiation of SSRIs, SNRIs, and non-benzodiazepine anxiolytics while maintaining restrictions on benzodiazepines and other medications with genuine abuse profiles. The current TPG framework fails to make this clinically essential distinction, treating sertraline one of the safest medications in the psychiatric pharmacopoeia identically to alprazolam, which has one of the highest abuse potentials among prescribed psychotropics.

The clinical rationale for the List B restriction is unclear. The American Psychiatric Association (APA) has endorsed tele-psychiatry as clinically appropriate for initial psychiatric evaluations and treatment initiation, including pharmacological prescribing, when conducted via synchronous video consultation that permits adequate clinical assessment (Shore et al., 2018). The UK's Royal College of Psychiatrists has similarly endorsed remote psychiatric assessment and prescribing, subject to clinical judgement about the appropriateness of the remote modality for the specific patient and condition (Royal College of Psychiatrists, 2020). India's blanket prohibition which applies regardless of clinical circumstances, the treating psychiatrist's expertise, or the severity of the patient's condition represents a regulatory outlier among major jurisdictions.

3.2. The Mental Healthcare Act 2017: The Telemedicine Lacuna

The Mental Healthcare Act 2017, which came into force on 29 May 2018, represents India's most comprehensive mental health legislation. The Act establishes the right to access mental healthcare (Section 18), including the right to affordable, good quality, and geographically accessible mental healthcare services. It creates the Central and State Mental Health Authorities, mandates the preparation of advance directives, establishes mental health review boards, regulates admission and treatment procedures, and decriminalises attempted suicide. The Act was lauded internationally as a progressive, rights-based approach to mental health governance (Duffy & Kelly, 2019).

However, the MHCA was drafted and enacted without any contemplation of telemedicine as a service delivery modality. The Act's provisions on the establishment of mental health institutions (Chapter V), admission procedures (Chapters IX-XII), and treatment standards (Sections 18-21) presuppose physical healthcare establishments and in-person interactions. Section 18(1) provides that every person shall have a right to access mental health care and treatment from mental health services run or funded by the appropriate Government, but does not specify whether "access" encompasses remote digital access. The Act's definition of "mental health establishment" under Section 2(1)(p) "any health establishment, including any hospital, nursing home, half-way home, rehabilitation centre" does not include digital platforms or telemedicine services.

A particularly compelling argument for the alignment of tele-psychiatry with the MHCA's philosophy emerges from Section 18(4) of the Act, which provides that every person with mental illness shall have a right to be treated in the least restrictive environment. This provision, drawn from the UN Convention on the Rights of Persons with Disabilities (CRPD) and the foundational principles of community psychiatry, establishes a hierarchy of care settings in which institutional confinement is the last resort and community-based, minimally intrusive care is the preferred modality. Tele-psychiatry, by its very nature, represents the least restrictive mental health service delivery modality: the patient receives care in their own home or community, without physical displacement, without exposure to the institutional environment of a psychiatric facility, and without the disruption to employment, family life, and social relationships that accompanies travel to distant mental health centres. Section 18(4) further provides for the right to community living, and tele-psychiatry is the technological enabler of community-based psychiatric care for the millions of Indians in rural communities where no psychiatrist practices. The Act's emphasis on the least restrictive environment also resonates with Section 18(2), which guarantees the right to live with dignity, free from cruel and inhuman treatment a principle that is violated when patients in remote areas must endure multi-day journeys, financial hardship, and social stigma merely to access a routine psychiatric follow-up appointment that could be safely conducted via video consultation. Thus, while the MHCA does not mention telemedicine, the philosophical and rights-based framework of the Act particularly the least-restrictive-environment principle and the right to community living not only accommodates but affirmatively supports tele-psychiatric service delivery as the modality most consistent with the Act's stated objectives.

This silence creates three specific legal uncertainties. First, it is unclear whether a tele-psychiatry platform qualifies as a "mental health establishment" subject to the MHCA's registration, inspection, and quality assurance requirements. If it does not, tele-psychiatric services operate outside the Act's regulatory oversight. If it does, current tele-psychiatry platforms would need to be registered with the Central or State Mental Health Authority, raising questions about registration criteria for digital services. Second, the Act's advance directive provisions (Sections 5-13) assume a treatment relationship with a specific mental health professional and establishment, but do not address how advance directives operate in the tele-psychiatric context where the treating professional may change between consultations and the "establishment" is a digital platform. Third, the Act's provisions on involuntary admission and treatment (Chapters X-XII) including the requirement for independent examination and mental health review board proceedings have no telemedicine-adapted procedures, creating legal uncertainty about when and how a tele-psychiatrist who identifies a patient in acute crisis should initiate involuntary processes.

3.3. Informed Consent in Tele-Psychiatry: The Unregulated Space

The TPG 2020 require practitioners to obtain patient consent before commencing a teleconsultation, specifying that consent may be "implied" when the patient initiates the consultation and "explicit" when the practitioner initiates it. This rudimentary consent framework falls far short of the requirements for mental health practice. Psychiatric treatment engages particularly sensitive dimensions of autonomy: the patient's decisional capacity may itself be affected by the condition being treated; pharmacological interventions carry significant side effects (weight gain, cognitive dulling, metabolic syndrome, extrapyramidal symptoms); and the therapeutic relationship involves disclosure of deeply personal information. The Supreme Court's articulation of informed consent principles in Samira Kohli v. Dr. Prabha Manchanda (2008) requiring disclosure of the nature and purpose of the procedure, its risks and consequences, and available alternatives has not been interpreted in the tele-psychiatric context.

Additionally, the remote modality introduces consent considerations absent from in-person consultations: the security and privacy of the communication platform; the possibility of recording; the limitations of remote assessment (inability to conduct physical examination, potential connectivity interruptions); and the procedures for managing emergencies during a teleconsultation. Neither the TPG nor the MHCA addresses these telemedicine-specific consent elements for mental health practice.

IV. THE UNITED STATES: CONTROLLED SUBSTANCE TELEMEDICINE AND STATE TELE-PSYCHIATRY REGULATION

4.1. The Ryan Haight Act and Its Telemedicine Exceptions

The United States' regulation of mental health telemedicine operates at two levels: federal controlled substance law and state medical practice regulation. At the federal level, the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 establishes the general rule that prescribing controlled substances (which include most psychotropic medications classified under the Controlled Substances Act) requires at least one in-person medical evaluation before the prescription is issued (U.S. Congress, 2008). This restriction parallels India's List B prohibition but, crucially, is subject to seven statutory exceptions enumerated in 21 U.S.C. § 802(54), including exceptions for practitioners acting within a DEA-registered telemedicine practice, Indian Health Service practitioners, VA practitioners, and practitioners operating during public health emergencies.

The COVID-19 pandemic catalysed a fundamental shift in US controlled substance telemedicine policy. In March 2020, the Drug Enforcement Administration (DEA), exercising authority under the public health emergency exception, issued guidance permitting the prescribing of Schedule II-V controlled substances via telemedicine without a prior in-person evaluation (DEA, 2020). This temporary flexibility was extended multiple times and, significantly, led to permanent regulatory changes. The Consolidated Appropriations Act 2023 extended telemedicine prescribing flexibilities, and the DEA proposed permanent rules in 2023 permitting the initial prescribing of non-narcotic Schedule III-V controlled substances (which include most antidepressants, anxiolytics, and antipsychotics) via telemedicine for up to a 30-day supply, after which an in-person evaluation would be required (DEA, 2023). This graduated approach permitting initial telemedicine prescribing with subsequent in-person follow-up requirements represents a nuanced middle ground between India's blanket prohibition and unrestricted prescribing.

4.2. State-Level Tele-Psychiatry Regulation

At the state level, the United States has developed a sophisticated and varied tele-psychiatry regulatory landscape. As of 2024, all fifty states and the District of Columbia permit the practice of tele-psychiatry, though with significant variations in specific requirements (Lacktman et al., 2023). State regulatory frameworks address several dimensions relevant to India's regulatory gap. On prescribing, most states follow the federal Ryan Haight framework but several including California, New York, and Texas have enacted state-specific provisions permitting broader tele-psychiatry prescribing within their borders. On licensure, the Interstate Medical Licensure Compact (IMLC) facilitates multi-state physician licensing, and several states have enacted specific tele-psychiatry licensure provisions enabling out-of-state psychiatrists to serve underserved areas.

On informed consent, multiple states have enacted tele-psychiatry-specific consent requirements that go beyond general telemedicine consent. For example, the American Psychiatric Association's Practice Guidelines for Telepsychiatry recommend that informed consent for tele-psychiatry include: the limitations of remote assessment; the protocols for managing psychiatric emergencies during teleconsultation; the security measures protecting the communication; the patient's right to refuse the telemedicine modality; and the contingency plan if technology fails during a session (Shore et al., 2018). Several states have adopted these guidelines as regulatory requirements. On reimbursement, the federal Mental Health Parity and Addiction Equity Act (MHPAEA) requires insurers to cover mental health services at parity with physical health services, and a growing number of states have enacted telehealth parity laws requiring equivalent reimbursement for tele-psychiatric and in-person psychiatric services (Cama et al., 2017).

4.3. Tele-Psychiatry in the VA System

The United States Department of Veterans Affairs (VA) operates the largest and most extensively studied tele-psychiatry programme globally, providing a critical evidence base for the proposition that tele-psychiatry can function safely and effectively at scale within a regulatory framework. The VA's telemental health programme, which began as a pilot in the late 1990s, had by 2023 delivered over 4.7 million telemental health encounters annually, serving approximately 1.3 million veterans across the continental United States, Alaska, Hawaii, and US territories (VA Office of Connected Care, 2023). The programme's scale is directly attributable to a regulatory advantage: the VA MISSION Act of 2018 authorised VA healthcare providers to practice telemedicine across state lines without obtaining additional state licences, effectively creating a federal preemption of state licensure barriers for VA telehealth (U.S. Congress, 2018). This single regulatory reform eliminated the interstate licensure fragmentation that continues to impede civilian tele-psychiatry and enabled the VA to deploy psychiatrists located in major urban medical centres to serve veterans in rural and tribal communities thousands of miles away.

The clinical outcomes evidence from the VA tele-psychiatry programme is particularly robust. A systematic review of VA telemental health studies found that tele-psychiatry achieved clinical outcomes equivalent to in-person care for major depressive disorder, PTSD, anxiety disorders, and substance use disorders, with high patient satisfaction and clinician acceptance (Connolly et al., 2020). The VA's tele-psychiatry programme for PTSD a condition disproportionately affecting veterans demonstrated that evidence-based treatments including Cognitive Processing Therapy (CPT) and Prolonged Exposure (PE) therapy could be delivered effectively via videoconference with comparable symptom reduction to in-person delivery (Morland et al., 2020). Crucially, the VA programme also demonstrated that remote psychiatric prescribing, including the prescribing of controlled substances for PTSD and anxiety disorders, could be conducted safely under appropriate clinical protocols without the blanket prohibitions that characterise India's regulatory approach.

The VA model is instructive for India for several reasons. First, it demonstrates that a single regulatory reform federal preemption of state licensure requirements can dramatically expand tele-psychiatric access across vast geographic distances, a lesson directly applicable to India's fragmented state medical registration system. Second, the VA's hub-and-spoke model, where specialist psychiatrists at tertiary VA medical centres provide consultations to primary care providers and patients at remote community-based outpatient clinics (CBOCs), offers a structural template for India's district hospital system, where primary care physicians could be supported by remote psychiatric consultation from specialists at NIMHANS, AIIMS, or state medical colleges. Third, the VA's extensive quality assurance infrastructure including standardised clinical protocols, mandatory provider training in telehealth delivery, encrypted VA Video Connect platform requirements, and systematic outcome monitoring demonstrates that tele-psychiatric services can operate within rigorous safety and quality frameworks without the blunt instrument of blanket prescribing prohibitions. The VA experience constitutes perhaps the strongest real-world evidence that tele-psychiatry, properly regulated, is not a compromise on quality but a mechanism for extending quality psychiatric care to populations that would otherwise receive none.

V. THE UNITED KINGDOM: INTEGRATED QUALITY ASSURANCE AND DIGITAL MENTAL HEALTH STANDARDS

5.1. CQC Regulation of Digital Mental Health Services

The United Kingdom's approach to mental health telemedicine regulation is characterised by integration within the existing healthcare quality assurance framework rather than separate telemedicine-specific legislation. The Care Quality Commission (CQC), as the independent regulator of health and social care in England, regulates all providers of remote mental health services under the same registration and inspection regime that applies to physical mental health services. The Health and Social Care Act 2008 (Regulated Activities) Regulations 2014 define regulated activities to include "treatment of disease, disorder or injury" and "assessment or medical treatment for persons detained under the Mental Health Act 1983," both of which encompass tele-psychiatric services (UK Parliament, 2014).

The CQC's inspection framework evaluates mental health services against five key questions:

- Are they safe?

- Are they effective?
- Are they caring?
- Are they responsive?
- Are they well-led?

For digital mental health services, the CQC has developed specific guidance addressing the unique risks of remote delivery, including: patient identification and verification procedures; protocols for assessing and managing acute psychiatric risk remotely; procedures for coordinating with local crisis teams when a remote patient presents with suicidal ideation or self-harm; data security and confidentiality standards; and clinical governance arrangements for remote prescribing (CQC, 2022). This integration of telemedicine within the existing regulatory framework, rather than creating a separate regime, ensures that digital mental health services are held to the same quality standards as physical services while addressing modality-specific risks.

5.2. NICE Guidelines and Remote Prescribing

The National Institute for Health and Care Excellence (NICE) provides clinical guidance that effectively governs tele-psychiatric practice through its evidence-based treatment recommendations. NICE guidelines for depression, anxiety disorders, psychosis, and other mental health conditions do not prohibit remote prescribing but emphasise clinical judgement about the appropriateness of the delivery modality. The NICE guideline on depression in adults (NG222), updated in 2022, explicitly recognises computerised cognitive behavioural therapy (cCBT) and remote delivery as appropriate treatment modalities, thereby legitimising digital mental health interventions within the evidence-based framework (NICE, 2022).

The UK's approach to psychotropic prescribing via telemedicine is governed by the General Medical Council's (GMC) Good Practice in Prescribing and Managing Medicines and Devices (General Medical Council, 2013), which applies equally to remote and in-person prescribing. The guidance permits remote prescribing where the prescriber has adequate knowledge of the patient's health and is satisfied that the medication serves the patient's needs, without imposing a blanket requirement for a prior in-person consultation. The Medicines and Healthcare products Regulatory Agency (MHRA) regulates the supply of medicines, including those prescribed via telemedicine, and has not imposed telemedicine-specific prescribing restrictions for psychotropic medications. This regulatory approach relying on professional judgement guided by clinical standards rather than blanket statutory prohibitions stands in stark contrast to India's categorical List B restriction.

5.3. The Montgomery Standard and Tele-Psychiatric Informed Consent

The UK's informed consent framework for tele-psychiatry benefits from the Supreme Court's landmark decision in Montgomery v. Lanarkshire Health Board (2015), which replaced the paternalistic Bolam standard with a patient-centred test. Under Montgomery, a doctor is under a duty to take reasonable care to ensure that the patient is aware of any material risks involved in any recommended treatment and of any reasonable alternative treatments. A risk is "material" if a reasonable person in the patient's position would be likely to attach significance to it, or if the doctor is or should reasonably be aware that the particular patient would be likely to attach significance to it (Montgomery v. Lanarkshire Health Board, 2015).

Applied to tele-psychiatry, the Montgomery standard requires disclosure of the specific limitations and risks of remote psychiatric assessment: the potential for missed clinical signs that would be apparent in person (such as psychomotor changes, tremor, or involuntary movements associated with medication side effects); the implications of technology failure during a consultation addressing sensitive material; the security and privacy characteristics of the communication platform; and the procedures for emergency intervention if the patient presents with acute risk during a remote session. The Royal College of Psychiatrists has issued specific guidance on conducting psychiatric assessments remotely, emphasising the need for risk assessment protocols, safety planning, and clear pathways for escalation to in-person care when clinically indicated (Royal College of Psychiatrists, 2020). This combination of judicial standard (Montgomery), professional guidance (Royal College), and regulatory oversight (CQC) creates a comprehensive informed consent architecture for tele-psychiatry that India entirely lacks.

5.4. NHS Digital Mental Health Services: IAPT and Digital CBT

The Improving Access to Psychological Therapies (IAPT) programme, launched in 2008 and subsequently rebranded as NHS Talking Therapies in 2023, represents the most ambitious national programme for expanding access to evidence-based psychological therapies globally and provides a compelling demonstration that technology-enabled mental health care can operate within existing quality frameworks at scale. IAPT was designed to address the treatment gap for common mental health disorders depression, generalised anxiety disorder, panic disorder, social anxiety, OCD, and PTSD by training a new workforce of psychological wellbeing practitioners and high-intensity therapists delivering NICE-approved therapies, principally cognitive behavioural therapy (CBT), within the NHS (Clark, 2011). By 2023, the programme was treating over 1.2 million people annually, with recovery rates consistently at or above 50% and reliable improvement rates exceeding 65%, making it one of the most systematically evaluated mental health programmes in the world (NHS Digital, 2023).

The integration of digital delivery within the IAPT programme has been progressive and instructive. Computerised CBT (cCBT) programmes including Beating the Blues, SilverCloud, and Ieso Digital Health have been incorporated as Step 2 interventions within IAPT's stepped-care model, where patients with mild-to-moderate symptoms are offered guided self-help and digital therapy before escalation to high-intensity face-to-face therapy if needed. NICE Technology Appraisal guidance (TA97) recommended computerised CBT for depression as early as 2006, and subsequent evaluations have confirmed that digital CBT achieves comparable outcomes to face-to-face CBT for mild-to-moderate depression and anxiety when delivered with appropriate clinical support and progress monitoring (Gilbody et al., 2017). During the COVID-19 pandemic, IAPT services rapidly transitioned to predominantly remote delivery telephone and video and published data showed that

clinical outcomes were maintained, with no significant deterioration in recovery rates compared to pre-pandemic in-person delivery (NHS England, 2021). This evidence directly challenges the assumption underlying India's TPG restrictions that mental health care delivered remotely is inherently inferior to in-person delivery.

The regulatory framework supporting IAPT's digital integration operates within the existing CQC, NICE, and NHS governance structures rather than requiring separate digital mental health legislation. Digital IAPT services are subject to: CQC registration and inspection; NICE approval of the specific digital interventions offered; NHS Data Security and Protection Toolkit compliance; clinical outcome monitoring through the IAPT minimum dataset, which collects session-by-session Patient Health Questionnaire (PHQ-9) and Generalised Anxiety Disorder (GAD-7) scores; and workforce regulation through the British Psychological Society and BABCP accreditation of therapists (NHS England, 2023). The IAPT model demonstrates three principles directly relevant to India's regulatory reform: first, that digital mental health services can achieve measurable clinical outcomes when embedded within evidence-based clinical frameworks; second, that technology-enabled mental health care can be integrated within existing quality assurance and regulatory structures rather than requiring entirely new regulatory regimes; and third, that systematic outcome monitoring which digital platforms facilitate more readily than paper-based clinic records can serve as a quality assurance mechanism that is actually superior to the input-focused inspection models traditionally applied to mental health services. India's Tele-MANAS programme, which currently functions primarily as a helpline rather than a structured therapy delivery platform, could draw on the IAPT model to evolve into a systematic digital mental health service delivery framework with embedded outcome measurement and quality assurance.

VI. COMPARATIVE ANALYSIS: KEY REGULATORY DIVERGENCES

A comparative assessment across the five regulatory dimensions reveals fundamental divergences that illuminate India's regulatory deficit.

On prescribing restrictions, India imposes the most restrictive regime among the three jurisdictions. The TPG 2020's List B prohibition on first-time psychotropic prescribing via telemedicine has no direct equivalent in the UK, where prescribing is governed by clinical judgement and professional standards, and is more restrictive than the US post-pandemic position, which permits initial prescribing of non-narcotic psychotropics with follow-up requirements. India's approach treats all psychotropic medications identically regardless of their risk profile, clinical indication, or the patient's circumstances, whereas both the US and UK differentiate by substance schedule, clinical context, and professional assessment.

On informed consent, the divergence is equally striking. The UK's Montgomery standard, supplemented by Royal College of Psychiatrists guidance, provides a comprehensive patient-centred consent framework specifically adapted for tele-psychiatric practice. The US's state-level tele-psychiatry consent requirements, particularly those adopting APA guidelines, address the specific dimensions of remote psychiatric assessment and treatment. India's TPG consent provisions implied consent when the patient initiates the call, explicit consent when the doctor initiates it make no distinction between a teleconsultation for a skin rash and a tele-psychiatric consultation for suicidal ideation.

On quality assurance, the UK's CQC registration and inspection regime ensures that digital mental health services are held to the same standards as physical services, with additional modality-specific requirements. The US system relies on state medical boards, specialty board certification, and accreditation bodies (such as the Joint Commission) to maintain quality standards for tele-psychiatric services. India has no quality assurance framework for tele-psychiatric services: telemedicine platforms are not required to meet any mental-health-specific standards, and neither the Central Mental Health Authority nor the State Mental Health Authorities exercise jurisdiction over digital mental health services.

On data protection for mental health records, all three jurisdictions recognise the heightened sensitivity of mental health information, but implement protections differently. HIPAA's Privacy Rule provides specific provisions for psychotherapy notes, requiring separate patient authorisation for their disclosure beyond treatment purposes a higher standard than for other PHI (U.S. Department of Health and Human Services, 2003). The UK GDPR classifies mental health data as special category data under Article 9, and the Caldicott Principles apply with particular force to mental health records given their sensitivity. India's DPDP Act 2023 provides no heightened protection for mental health data, and the TPG 2020 do not address mental health data governance specifically.

On cross-jurisdictional practice, the US's IMLC and state-specific tele-psychiatry licensure provisions, while imperfect, enable psychiatrists to serve patients across state lines. The UK's national registration through the GMC eliminates cross-jurisdictional barriers entirely. India's state-based medical registration system, coupled with the TPG 2020's ambiguous implication that registration in any state suffices for telemedicine practice, creates legal uncertainty that particularly affects tele-psychiatry, where the scarcity of psychiatrists makes cross-state practice essential for reaching underserved populations.

Synthesising the analysis across all five regulatory dimensions, a structured comparison clarifies the precise contours of India's regulatory deficit. On Dimension 1 (prescribing), the UK operates on a professional-judgement model with no blanket telemedicine prescribing restrictions for psychotropics, the US has moved to a graduated model permitting initial prescribing of non-narcotic psychotropics with time-limited supply and follow-up requirements, and India maintains a blanket prohibition on first-time psychotropic prescribing via telemedicine regardless of clinical context, drug safety profile, or prescriber qualification. On Dimension 2 (informed consent), the UK applies the patient-centred Montgomery standard supplemented by Royal College of Psychiatrists tele-psychiatry-specific guidance, the US applies state-specific tele-psychiatry consent requirements frequently incorporating APA guidelines addressing remote assessment limitations and emergency protocols, and India applies a generic telemedicine consent framework with no mental-health-specific provisions. On Dimension 3 (quality assurance), the UK integrates digital mental health services within CQC registration and inspection with modality-specific guidance, the US relies on state medical boards, Joint Commission accreditation, and specialty certification with the VA system providing a federal quality model, and India has no quality assurance framework whatsoever for tele-psychiatric services. On Dimension 4 (data protection), the UK classifies mental health data as special category data under UK GDPR with Caldicott Guardian oversight, the US provides specific HIPAA protections for psychotherapy notes with a higher

disclosure authorisation threshold, and India provides no heightened protection for mental health data under the DPDP Act 2023. On Dimension 5 (cross-jurisdictional practice), the UK eliminates barriers through national GMC registration, the US has partially addressed them through the IMLC and the VA MISSION Act's federal preemption, and India's fragmented state medical registration system creates unresolved legal uncertainty for cross-state tele-psychiatric practice. Across every dimension, India's framework is either the most restrictive, the least developed, or entirely absent, creating a cumulative regulatory deficit that is incompatible with the constitutional imperative to ensure access to mental healthcare.

VII. LEGAL BARRIERS SPECIFIC TO INDIAN TELE-PSYCHIATRY: A CRITICAL ASSESSMENT

Beyond the regulatory gaps identified through comparative analysis, Indian tele-psychiatry faces additional legal barriers rooted in the domestic legal framework. The intersection of the MHCA 2017 and the TPG 2020 creates a regulatory gap regarding the capacity assessment of psychiatric patients in teleconsultation. The MHCA establishes a presumption of capacity (Section 4) and detailed procedures for determining when a person lacks capacity to make mental healthcare decisions. However, assessing decisional capacity via teleconsultation a process that requires evaluation of understanding, appreciation, reasoning, and ability to express a choice presents clinical challenges that the regulatory framework does not address. A tele-psychiatrist who determines that a patient lacks capacity faces legal uncertainty about the validity of this assessment and the procedural steps available for initiating supported or substituted decision-making under the MHCA's provisions.

The liability framework for tele-psychiatric practice in India is similarly uncertain. The Supreme Court's articulation of the medical negligence standard in Jacob Mathew v. State of Punjab (2005) requiring proof of a duty of care, a breach constituting deviation from accepted medical practice, and resulting damage was developed in the context of in-person medical practice. The "accepted medical practice" standard presupposes the existence of accepted practices for the modality in question. For tele-psychiatry, which has no Indian clinical practice guidelines, court-recognised treatment protocols, or professional body standards, the standard against which a tele-psychiatrist's conduct would be judged is undefined. This legal uncertainty creates a chilling effect on tele-psychiatric practice: psychiatrists who would otherwise be willing to provide remote care may refrain from doing so because of unpredictable liability exposure (Bajpai, 2013).

A particularly acute legal lacuna concerns emergency tele-psychiatric care. Consider a scenario by no means hypothetical in which a patient in a remote tribal district of Odisha or Jharkhand, where the nearest psychiatrist is 200 kilometres away, accesses a tele-psychiatric consultation and, during the session, discloses active suicidal ideation with a specific plan. The tele-psychiatrist faces a clinical emergency with no legal roadmap. The MHCA 2017, while decriminalising attempted suicide under Section 115 and mandating that such individuals be presumed to be under severe stress requiring treatment, provides no mechanism for the tele-psychiatrist to initiate emergency intervention remotely. The Act's emergency admission provisions (Section 94) require a medical practitioner to personally examine the person and certify that the person has a mental illness of such severity that immediate in-patient treatment is required language that presupposes physical presence. The TPG 2020 simply state that if the condition warrants it, the practitioner should advise the patient to visit a healthcare facility, guidance that is dangerously inadequate when the patient is in active psychiatric crisis. By contrast, the UK's CQC-mandated framework for remote mental health services requires providers to establish pre-consultation safety protocols, including: confirming the patient's physical location at the start of every teleconsultation; maintaining current local crisis team contact information for the patient's area; having a documented escalation pathway from remote consultation to local emergency services; and conducting a risk assessment at the beginning and end of every session (CQC, 2022). The UK's Crisis Resolution and Home Treatment Teams (CRHTTs) provide 24/7 community-based crisis response that can be activated by a remote clinician, creating a coordinated system in which tele-psychiatric assessment and local emergency response function as an integrated service. India requires an analogous framework: a statutory obligation on tele-psychiatric providers to establish emergency coordination protocols with district-level health authorities, police, and emergency services, coupled with a safe harbour provision protecting tele-psychiatrists who activate emergency interventions in good faith from liability for any consequences of the remote nature of the initial assessment.

The Consumer Protection Act 2019 compounds this uncertainty. The Supreme Court in Indian Medical Association v. V.P. Shantha (1995) established that medical services fall within the ambit of consumer protection law. For tele-psychiatry, this creates questions about the appropriate forum for complaint adjudication: the consumer commission of the patient's location, the doctor's location, or the platform's registered office? The CPA 2019's jurisdictional provisions (Sections 28-34) do not contemplate disputes arising from remote service delivery across state boundaries, creating forum-shopping opportunities and jurisdictional conflicts.

VIII. RECOMMENDATIONS FOR REGULATORY REFORM

Based on this comparative analysis, the following reforms are proposed to align India's regulatory framework with the requirements of effective tele-psychiatric service delivery.

8.1. Reform the TPG 2020 Prescribing Restrictions

The List B blanket prohibition on first-time psychotropic prescribing via telemedicine should be replaced with a graduated framework modelled on the US post-pandemic approach. Specifically:

- Non-controlled psychotropic medications commonly prescribed for depression, anxiety, and insomnia (ssris, snris, non-benzodiazepine anxiolytics) should be reclassified to permit first-time prescribing via synchronous video consultation by a qualified psychiatrist, subject to a maximum initial supply of 30 days and a requirement for follow-up within that period;

- Controlled psychotropic medications (benzodiazepines, certain mood stabilisers) should remain subject to the prior-prescription requirement but with a clearly defined exception pathway for psychiatrists serving areas with no in-person psychiatric services;
- The List C prohibition on NDPS Act substances should be maintained for telemedicine prescribing.

8.2. Amend the Mental Healthcare Act 2017

The MHCA should be amended to explicitly incorporate telemedicine-based mental health service delivery. Specifically:

- The definition of "mental health establishment" should be expanded to include telemedicine platforms providing mental health services, subject to appropriate registration criteria adapted for digital services;
- Provisions on advance directives should be updated to address the tele-psychiatric treatment context;
- Procedures for emergency intervention when a patient presents with acute psychiatric risk during a teleconsultation should be established, including coordination protocols with local crisis teams and emergency services;
- The central and state mental health authorities should be empowered to regulate and inspect digital mental health services.

8.3. Develop National Tele-Psychiatry Practice Standards

The National Medical Commission, in consultation with NIMHANS and professional psychiatric associations, should develop comprehensive tele-psychiatry practice standards addressing: clinical assessment protocols for remote psychiatric evaluation; informed consent requirements specific to tele-psychiatric consultations, aligned with the Montgomery standard's patient-centred approach; capacity assessment procedures for teleconsultation; safety planning and risk management protocols for remote psychiatric care; minimum technical requirements for tele-psychiatric platforms (video quality, encryption, recording policies); documentation standards for tele-psychiatric encounters; and training requirements for practitioners offering tele-psychiatric services. These standards would provide the "accepted medical practice" benchmark needed to operationalise the Jacob Mathew negligence standard for tele-psychiatric care.

8.4. Establish Mental Health Data Protection Standards

Given the heightened sensitivity of mental health data, specific protections should be established either within the DPDP Act framework or through sector-specific regulation: mental health consultation records should be classified as requiring enhanced protections, analogous to HIPAA's psychotherapy notes provisions; telemedicine platforms offering mental health services should be subject to mandatory security assessments; patients should have the right to restrict sharing of mental health records beyond the treating clinician; and anonymised mental health telemedicine data should be made available for research to build the evidence base for tele-psychiatric practice in the Indian context.

8.5. Leveraging ASHA Workers for Tele-Psychiatric Service Delivery

India possesses a unique community health infrastructure that, with appropriate regulatory support, could transform tele-psychiatric service delivery in rural areas: the network of approximately one million Accredited Social Health Activists (ASHA workers) operating under the National Health Mission. ASHA workers, who function as community-level health facilitators in every village across India, have demonstrated their effectiveness in maternal and child health, immunisation, and communicable disease programmes. Their integration into tele-psychiatric service delivery offers a solution to the 'last mile' challenge that purely technology-based approaches cannot address: many rural patients lack the digital literacy, internet connectivity, or private space required for independent tele-psychiatric consultations. Under the proposed model, ASHA workers would be trained as tele-psychiatric facilitators not as mental health practitioners, but as community-level coordinators who identify individuals requiring mental health support, facilitate teleconsultation sessions using portable devices at sub-centre or panchayat-level facilities, assist patients in communicating symptoms and concerns to the remote psychiatrist, and support treatment adherence through regular follow-up visits (Patel et al., 2016).

The regulatory framework for ASHA worker integration in tele-psychiatric services would require several elements. First, the National Health Mission's ASHA training curriculum would need to include a mental health module covering basic mental health literacy, recognition of common psychiatric symptoms, crisis identification (particularly suicidal ideation and psychotic symptoms), and the operational procedures for facilitating teleconsultations. The District Mental Health Programme, which currently operates in fewer than half of India's districts, could serve as the administrative framework for deploying ASHA-facilitated tele-psychiatric services, with district hospitals serving as the hub for specialist tele-psychiatric consultations. Second, the TPG 2020 would need to be amended to recognise ASHA-facilitated teleconsultations as a legitimate modality, including provisions clarifying that the treating psychiatrist's duty of care is owed to the patient and not delegated to the ASHA worker, and that the ASHA worker's role is facilitative rather than clinical. Third, confidentiality protocols must be established to protect patient privacy during ASHA-facilitated consultations, including requirements for private consultation spaces and restrictions on the ASHA worker's access to clinical information beyond what is necessary for facilitation. Fourth, the National Medical Commission should develop specific clinical guidelines for ASHA-facilitated tele-psychiatric consultations, addressing the modified clinical assessment process when a non-clinical facilitator is present and the enhanced documentation requirements. This model draws on the VA's successful hub-and-spoke framework and the UK's IAPT stepped-care model, adapted to India's unique community health infrastructure, and has the potential to extend tele-psychiatric services to the most underserved rural populations where neither in-person psychiatry nor independent tele-psychiatry is currently feasible.

IX. CONCLUSION

India's mental health crisis is a crisis of access, and telemedicine offers a technologically proven mechanism for expanding that access to the estimated 150 million Indians with untreated mental health conditions. The regulatory barriers identified in this article blanket psychotropic prescribing restrictions, the Mental Healthcare Act's silence on telemedicine, absent informed consent standards, undefined liability frameworks, and inadequate data protections are not inherent limitations of the technology but regulatory choices that can and should be reformed.

The comparative analysis demonstrates that both the United States and the United Kingdom have developed sophisticated regulatory frameworks that balance legitimate safety concerns with the imperative of expanding mental health access. The US model shows that controlled substance prescribing restrictions can be graduated rather than absolute, differentiating by substance risk, clinical context, and prescriber qualification. The UK model demonstrates that quality assurance for digital mental health services can be integrated within existing regulatory architecture through CQC registration and inspection, professional body guidance, and the patient-centred Montgomery consent standard.

India's path forward does not require wholesale importation of foreign models but targeted adaptation of proven regulatory mechanisms to the Indian constitutional and institutional context. The reforms proposed in this article graduated prescribing restrictions, MHCA amendments for telemedicine integration, national tele-psychiatry practice standards, and enhanced mental health data protections are feasible within existing institutional structures and constitutional authority. The right to mental healthcare, affirmed by the MHCA 2017 and rooted in Article 21 of the Constitution, imposes an affirmative obligation on the state to remove barriers to healthcare access. When those barriers are regulatory rather than technological, the imperative for reform is both legal and moral. The 83% treatment gap is not a statistic to be cited and lamented but a regulatory failure to be identified and corrected. India's digital minds deserve more than analog laws.

REFERENCES

Bajpai, V. (2013). The challenges confronting public hospitals in India, their origins, and possible solutions. *Advances in Public Health, 2013*, Article 898502.

Board of Governors in supersession of Medical Council of India. (2020). *Telemedicine practice guidelines: Enabling registered medical practitioners to provide healthcare using telemedicine*. MCI.

Cama, S., Malowney, M., Engelman, D. D., Patel, M., & Boyd, J. W. (2017). An analysis of the status of state telehealth mental health parity laws. *Psychiatric Services, 68*(10), 1076–1078.

Care Quality Commission. (2022). *The state of health care and adult social care in England 2021/22*. CQC.

Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., … Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. *The Lancet, 391*(10128), 1357–1366.

Clark, D. M. (2011). Implementing NICE guidelines for the psychological treatment of depression and anxiety disorders: The IAPT experience. *International Review of Psychiatry, 23*(4), 318–327.

Connolly, S. L., Miller, C. J., Lindsay, J. A., & Bauer, M. S. (2020). A systematic review of providers' attitudes toward telemental health via videoconferencing. *Clinical Psychology: Science and Practice, 27*(2), e12311.

Drug Enforcement Administration. (2020). *DEA qualifying practitioners: COVID-19 telemedicine prescribing.*

Drug Enforcement Administration. (2023). Proposed rule: Telemedicine prescribing of controlled substances when the practitioner and the patient have not had a prior in-person medical evaluation. *Federal Register, 88*(41), 12890–12928.

Duffy, R. M., & Kelly, B. D. (2019). India's Mental Healthcare Act, 2017: Content, context, controversy. *International Journal of Law and Psychiatry, 62*, 169–178.

General Medical Council. (2013). *Good practice in prescribing and managing medicines and devices.*

Gilbody, S., Littlewood, E., Hewitt, C., Brierley, G., Tharmanathan, P., Araya, R., … White, D. (2017). Computerised cognitive behaviour therapy (cCBT) as treatment for depression in primary care (REEACT trial): Large scale pragmatic randomised controlled trial. *BMJ, 356*, j195.

Hilty, D. M., Ferrer, D. C., Parish, M. B., Johnston, B., Callahan, E. J., & Yellowlees, P. M. (2013). The effectiveness of telemental health: A 2013 review. *Telemedicine and e-Health, 19*(6), 444–454.

Hubley, S., Lynch, S. B., Schneck, C., Thomas, M., & Shore, J. (2016). Review of key telepsychiatry outcomes. *World Journal of Psychiatry, 6*(2), 269–282.

Indian Medical Association v. V. P. Shantha, (1995) 6 SCC 651.

Jacob Mathew v. State of Punjab, (2005) 6 SCC 1.

K. S. Puttaswamy v. Union of India, (2017) 10 SCC 1.

Lacktman, N., Acosta, J., & Levine, S. (2023). *State telehealth laws and reimbursement policies report*. CCHP.

Lader, M. (2011). Benzodiazepines revisited—Will we ever learn? *Addiction, 106*(12), 2086–2109.

Lakhan, R., Agrawal, A., & Sharma, M. (2022). Prevalence of depression, anxiety, and stress during COVID-19 pandemic in India: A systematic review and meta-analysis. *Indian Journal of Psychiatry, 64*(1), 25–34.

Ministry of Health and Family Welfare. (2024). *Tele-MANAS: National tele mental health programme progress report.*

Montgomery v. Lanarkshire Health Board, [2015] UKSC 11.

Morland, L. A., Poizner, J. M., Williams, K. E., Masino, T. T., & Thorp, S. R. (2020). Home-based clinical video teleconferencing care: Clinical considerations and future directions. *International Review of Psychiatry, 32*(3), 198–210.

Murthy, P. (2020). COVID-19 pandemic and substance use disorders in India. *Indian Journal of Psychiatry, 62*(Suppl. 3), S270–S276.

Murthy, R. S. (2017). National mental health survey of India 2015–2016. *Indian Journal of Psychiatry, 59*(1), 21–26.

National Crime Records Bureau. (2022). *Accidental deaths and suicides in India 2021*.

National Health Accounts. (2020). *National health accounts estimates for India 2017–18*.

National Institute for Health and Care Excellence. (2022). *Depression in adults: Treatment and management (NG222)*.

National Institute of Mental Health and Neurosciences. (2016). *National mental health survey of India 2015–16: Summary*.

NHS Digital. (2023). *Psychological therapies: Annual report on the use of IAPT services, 2022–23*.

NHS England. (2021). *The IAPT manual* (Version 5).

NHS England. (2023). *NHS talking therapies for anxiety and depression: Service specification*.

Parliament of India. (2017). *Mental Healthcare Act, 2017 (Act No. 10 of 2017)*.
Paschim Banga Khet Mazdoor Samity v. State of West Bengal, (1996) 4 SCC 37.
Patel, V., Chisholm, D., Parikh, R., Charlson, F. J., Degenhardt, L., Dua, T., … Whiteford, H. (2016). Addressing the burden of mental, neurological, and substance use disorders: Key messages from Disease Control Priorities. *The Lancet, 387*(10028), 1672–1685.
Royal College of Psychiatrists. (2020). *Remote consultations in psychiatry: Guidance for clinicians (CR232)*.
Samira Kohli v. Dr. Prabha Manchanda, (2008) 2 SCC 1.
Shidhaye, R., & Kermode, M. (2013). Stigma and discrimination as a barrier to mental health service utilization in India. *International Health, 5*(1), 6–12.
Shore, J. H., Yellowlees, P., Caudill, R., McVeigh, F. L., Dunn, L. A., Moreno, F. A., … Hilty, D. M. (2018). Best practices in videoconferencing-based telemental health. *Telemedicine and e-Health, 24*(11), 827–840.
UK Parliament. (2014). *Health and Social Care Act 2008 (Regulated Activities) Regulations 2014 (SI 2014/2936)*.
U.S. Congress. (2008). *Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (Pub. L. No. 110-425)*.
U.S. Congress. (2018). *VA MISSION Act of 2018 (Pub. L. No. 115-182)*.
U.S. Department of Health and Human Services. (2003). Standards for privacy of individually identifiable health information: Final rule. *Federal Register, 68*(34), 8334–8381.
VA Office of Connected Care. (2023). *VA telehealth: Connecting veterans to care*.
World Health Organization. (2022). *World mental health report: Transforming mental health for all*.